EdiShorts

Surrogate Advertising and Celebrity Endorsement: The Vimal Elaichi Crackdown

IssueAugust 2026
PaperGS Paper 2
SubjectPolity & Governance
Read time5 min

Context: The Maharashtra FDA's move to question celebrity endorsers of products like Vimal Elaichi, alleging surrogate advertising for tobacco, has sparked debate. This action highlights the critical issue of misleading advertisements and their impact on public health, making it a key topic for UPSC aspirants.

Key Facts

  • India bears the world's largest burden of oral cancer.
  • The Maharashtra FDA is targeting celebrity endorsements of products like Vimal Elaichi.
  • The Consumer Protection Act 2019 introduced endorser liability.

Key Points

  • The Maharashtra FDA's action against celebrity endorsements for products like Vimal Elaichi is an attempt to curb surrogate advertising, particularly for tobacco products.
  • This move addresses the asymmetry where celebrities gain from endorsements without bearing the health risks associated with the advertised products.
  • The FDA's suspicion is that Vimal Elaichi is endorsed as a surrogate for tobacco, a reading supported by the Cigarettes and Other Tobacco Products Act (COTPA) Rules.
  • The Delhi High Court ruling in DGHS vs Som Pan Product Pvt. Ltd. (2024) stated that the state must prove surrogate advertising, not rely solely on brand registration or the legality of a product.
  • The issue extends beyond tobacco to products making unsubstantiated health claims and financial products, indicating a broader regulatory challenge.
  • The Consumer Protection Act 2019 has introduced endorser liability, making celebrities accountable and limiting their defence of ignorance.
  • India's fragmented regulatory regime across multiple Acts and Rules complicates the effective control of problematic advertisements.
  • Successful enforcement by the FDA could significantly reduce the space for surrogate advertising and protect consumer health, especially concerning oral cancer.

Background

  • Surrogate advertising is a long-standing issue in India, particularly for products like alcohol and tobacco, which are banned from direct advertising.
  • Celebrity endorsements have historically been used to build brand recall and trust, often overshadowing the actual product's risks or efficacy.
  • Previous attempts to regulate advertising have faced challenges due to legal interpretations and the complexity of proving intent behind endorsements.

Why It Matters

  • Protecting public health is paramount, especially given India's high burden of oral cancer linked to tobacco consumption.
  • Ensuring fair trade practices and preventing consumer deception is crucial for market integrity and consumer trust.
  • Holding celebrities accountable sets a precedent for responsible endorsement and discourages the exploitation of public influence for harmful products.
  • Effective regulation can curb the economic incentives for manufacturers to promote harmful products indirectly.

Challenges

  • The legal burden of proof lies with the state to demonstrate surrogate advertising, which can be challenging.
  • The fragmented nature of Indian laws and regulatory bodies creates loopholes and difficulties in coordinated enforcement.
  • The influence of celebrities and the substantial advertising budgets of manufacturers make regulatory oversight a constant challenge.
  • Balancing freedom of commercial speech with the need to protect public health and prevent consumer deception is a delicate act.

Government Initiatives

  • Consumer Protection Act 2019: Introduced provisions for endorser liability and hefty penalties for misleading advertisements.
  • Cigarettes and Other Tobacco Products Act (COTPA) Rules: Prohibit direct and indirect advertising of tobacco products.
  • Food Safety and Standards Act 2006: Regulates food products and their advertising, ensuring safety and preventing misleading claims.

Way Forward

  • Strengthen enforcement mechanisms under COTPA and the Food Safety and Standards Act 2006 to withstand legal scrutiny.
  • Develop clearer guidelines and a more unified regulatory approach to define and identify surrogate advertising.
  • Increase penalties for violations to act as a significant deterrent for both manufacturers and endorsers.
  • Promote greater due diligence by celebrities and advertising agencies regarding the products they endorse.
  • Enhance public awareness campaigns about the dangers of tobacco and misleading health claims.

Exam Angle — Prelims & Mains

  • UPSC PYQ Link (Mains 2023, GS Paper II): "Critically examine the effectiveness of the Consumer Protection Act, 2019 in safeguarding consumer interests against misleading advertisements and unfair trade practices in the digital age." — Focus on the new provisions like endorser liability and how they address challenges posed by online advertising and surrogate promotions.
  • Practice Mains Question (GS Paper II, 15 marks, 250 words): Critically analyze the challenges posed by surrogate advertising in India, particularly concerning public health, and evaluate the adequacy of the existing regulatory framework in addressing these issues.
  • Prelims Angle: Remember the Consumer Protection Act 2019, its provisions on endorser liability, and the general issue of surrogate advertising which often involves products like tobacco and alcohol. Associate 'endorser liability' with the 2019 Act and 'surrogate advertising' with products like tobacco/alcohol.
    • Practice Prelims MCQ: With reference to surrogate advertising in India, consider the following statements:
      1. The Cigarettes and Other Tobacco Products Act (COTPA) Rules explicitly prohibit the advertising of tobacco products through brand extensions.
      2. The Consumer Protection Act 2019 introduced provisions for holding celebrity endorsers liable for misleading advertisements.
      3. The Delhi High Court has held that regulatory bodies must prove a case of surrogate advertising, not rely solely on brand registration.
      Which of the statements given above is/are correct?
      Options:
      (A) 1 and 2 only
      (B) 2 and 3 only
      (C) 1 and 3 only
      (D) 1, 2 and 3
      Show answer
      Answer: (B) 2 and 3 only — Statement 1 is INCORRECT — While COTPA prohibits direct and indirect advertising, the editorial doesn't explicitly state it prohibits 'brand extensions' as a specific mechanism for surrogate advertising, but rather that the *practice* is targeted. Statement 2 is CORRECT — The Consumer Protection Act 2019 introduced endorser liability. Statement 3 is CORRECT — The editorial cites the Delhi High Court's ruling in DGHS vs Som Pan Product Pvt. Ltd. (2024) to this effect.

More Polity & Governance from August 2026

Written by the EdiShorts editorial team from official and public sources. Check the latest position before quoting figures in the exam.